Polycyclo Ring System Having The Diazole Ring As One The Cyclos Patents (Class 548/301.7)
  • Patent number: 10392387
    Abstract: Thermally assisted delayed fluorescent materials with triad-type materials for use in full color displays and lighting applications with the following generic structures are provided:
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: August 27, 2019
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventor: Jian Li
  • Patent number: 10144739
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: December 4, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Joachim Broeker, Nina Kerres, Christiane Kofink, Juergen Ramharter, Harald Weinstabl
  • Patent number: 9181280
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: November 10, 2015
    Assignee: PHARMACYCLICS LLC
    Inventors: Daniel A. Dickman, Dange Vijay Kumar, Colin O'Bryan, Roopa Rai, William Dvorak Shrader
  • Patent number: 9101600
    Abstract: Heterocyclic compounds, and pharmaceutical compositions thereof, are disclosed as ROR?t modulators that have a formula represented by the following: and wherein n1, n2, R1, R2, R3, and R4 are as described herein. These compounds may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: August 11, 2015
    Assignees: New York University, The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Dan Littman, Jun R. Huh, Wenwei Huang, Ruili Huang
  • Publication number: 20150137083
    Abstract: Conjugated aromatic derivatives having an electron donating group and an electron accepting group at each end are provided. The conjugated aromatic derivatives of the present invention may be provided with blue light-emitting property and may be applied as a host material, a dopant material, an electron transporting material or a hole transporting material. An OLED device using the conjugated aromatic derivatives is also herein disclosed.
    Type: Application
    Filed: April 16, 2014
    Publication date: May 21, 2015
    Applicant: National Tsing Hua University
    Inventors: Chien-Hong CHENG, Chih-Chun LIN
  • Publication number: 20150123089
    Abstract: The present application provides a new nitrogen-containing heterocyclic compound and an organic electronic device using the same.
    Type: Application
    Filed: April 12, 2013
    Publication date: May 7, 2015
    Inventors: Dong Hoon Lee, Tae Yoon Park, Sung Kil Hong, Boonjae Jang, Minseung Chun, Dong Sik Kim, Minyoung Kang
  • Publication number: 20150118758
    Abstract: Methods, compositions, and systems for detecting gamma radiation is disclosed and described. A compound for detecting gamma radiation can comprise a conjugated imidazole having the following structure: [Formula I] where at least one of R1, R2, and R3 are conjugated organic groups. Additionally, the conjugated imidazole can be capable of reacting with a radical or ion formed by the reaction of gamma radiation with a radical generating component such as a halogen solvent to decrease a molar extinction coefficient of the conjugated imidazole in the visible light region or to quench fluorescence of the conjugated imidazole. As a sensor (100), a radiation detection indicator (108) can indicate the change in molar extinction coefficient or fluorescence of the conjugated imidazole material (120) upon exposure to gamma radiation.
    Type: Application
    Filed: May 24, 2013
    Publication date: April 30, 2015
    Applicant: University of Utah Research Foundation
    Inventors: Ling Zang, Jimin Han, Xu Miao
  • Patent number: 8993607
    Abstract: The invention provides compounds of formula I, II, and III as defined herein, as well as salts thereof. The compounds may have activity as anti-proliferative agents.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: March 31, 2015
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Edmond J. LaVoie, Joseph E. Rice
  • Patent number: 8981113
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein R0, R1, R2, R3, R4 and a are defined herein.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: March 17, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark J Macielag, Mingde Xia, Xiaoqing Xu
  • Patent number: 8927587
    Abstract: The invention relates to benzimidazole and imidazopyridine derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new Nav1.8 modulators of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7. X and Y are as defined in the description. Nav1.8 modulators are potentially useful in the treatment of a wide range of disorders, particularly pain.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: January 6, 2015
    Assignee: Pfizer LImited
    Inventors: Sharanjeet Kaur Bagal, Alan Daniel Brown, Mark Ian Kemp, Wolfgang Klute, Laia Malet Sanz, Brian Edward Marron, Duncan Charles Miller, Sarah Elizabeth Skerratt, Mark J. Suto, Christopher William West
  • Publication number: 20140374706
    Abstract: Disclosed are a compound for an organic optoelectric device, an organic optoelectric device including the same and a display device including the organic optoelectric device, wherein the compound for an organic optoelectric device is represented by the following Chemical Formula 1, In the above Chemical Formula 1, R1 to R7, X, L1 and L2 are the same as described in the detailed description.
    Type: Application
    Filed: November 20, 2013
    Publication date: December 25, 2014
    Inventors: Jin-Seok HONG, Dong-Min KANG, Eun-Sun YU, Soo-Young JEONG, Ji-Hun SHIN, Dong-Kyu RYU, Han-ill LEE, Yu-Na JANG
  • Publication number: 20140319473
    Abstract: A compound represented by Formula 1 below and an organic light-emitting device including the compound are provided: Substituents in Formula 1 are the same as defined in the specification.
    Type: Application
    Filed: September 13, 2013
    Publication date: October 30, 2014
    Applicant: Samsung Display Co., Ltd.
    Inventor: Jung-Sub Lee
  • Publication number: 20140316144
    Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: June 26, 2014
    Publication date: October 23, 2014
    Inventors: Elizabeth M. Bacon, Jeromy J. Cottell, John O. Link, Teresa Alejandra Trejo Martin
  • Publication number: 20140309432
    Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: April 24, 2014
    Publication date: October 16, 2014
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Elizabeth M. Bacon, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, Evan S. Krygowski, John O. Link, James Taylor, Chinh Viet Tran, Teresa Alejandra Trejo Martin, Zheng-Yu Yang, Sheila Zipfel
  • Patent number: 8796253
    Abstract: This invention relates to novel heteroaryl substituted pyrazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients or therapeutic measures.
    Type: Grant
    Filed: May 8, 2008
    Date of Patent: August 5, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Stephen Boyer, Michael Härter, Philip Wickens, Manoj Patel, Ellalahewage Sathyajith Kumarasinghe, Ajay Kumar Bhargava, Karl-Heinz Thierauch, Hartmut Beck, Susanne Greschat, Peter Ellinghaus, Patrick Paulus, Holger Hess-Stumpp
  • Publication number: 20140178336
    Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: March 14, 2013
    Publication date: June 26, 2014
    Inventor: Gilead Sciences, Inc.
  • Publication number: 20140151661
    Abstract: An amine derivative having a phenanthroimidazole group, an organic electroluminescence material, and an electroluminescence device, the amine derivative being represented by Formula 1, below:
    Type: Application
    Filed: November 27, 2013
    Publication date: June 5, 2014
    Applicant: SAMSUNG DISPLAY CO., LTD.
    Inventor: Yasuo MIYATA
  • Patent number: 8729117
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: May 20, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Daniel A. Dickman, Dange Vijay Kumar, Colin O'Bryan, Roopa Rai, William Dvorak Shrader
  • Publication number: 20140112885
    Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: October 8, 2013
    Publication date: April 24, 2014
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Elizabeth M. Bacon, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, Evan S. Krygowski, John O. Link, James Taylor, Chinh Viet Tran, Teresa Alejandra Trejo Martin, Zheng-Yu Yang, Sheila Zipfel
  • Publication number: 20140051689
    Abstract: Compounds of formula (I), and their use as in the treatment of infections involving viruses of the Pneumovirinae sub-family (RSV) are disclosed. In the formula ring (A) may be phenyl, pyridyl etc., (B-C) may be CH2—CH2 etc., (R1) may be phenyl and substituted forms thereof, (R2) may be assorted substituents.
    Type: Application
    Filed: October 24, 2013
    Publication date: February 20, 2014
    Applicant: Biota Scientific Management Pty Ltd.
    Inventors: Silas Bond, Vanessa Anne Sanford, John Nicholas Lambert, Chin Yu Lim, Alistair George Draffan, Roland Henry Nearn, Jeffrey Peter Mitchell
  • Publication number: 20140027741
    Abstract: Heterocyclic compounds, synthetic methods for preparing the same, and organic light-emitting display devices comprising the same are described. The subject heterocyclic compounds may comprise an aromatic ring or a heteroaromatic ring fused with a carbazole, dibenzothiophene, or dibenzofurane derivative, the compounds featuring rigid backbone structures with high glass transition temperatures and high melting points. The subject heterocyclic compounds may exhibit high electrical stability, improved charge transport ability, high heat resistance and improved light-emitting properties when used in organic light-emitting devices. Organic light-emitting display devices prepared according to the present invention exhibit lower driving voltages, increased luminescent efficiencies and longer lifetimes.
    Type: Application
    Filed: June 17, 2013
    Publication date: January 30, 2014
    Inventors: Bum-Woo PARK, Yoon-Hyun KWAK, Sun-Young LEE, Jong-Won CHOI, Wha-Il CHOI, So-Yeon KIM, Ji-Youn LEE, Jin-Young YUN
  • Publication number: 20140027755
    Abstract: The present invention relates to an electronic device comprising one or more compounds of a formula (I) or (II). Furthermore, the invention encompasses the use of a compound of the formula (I) or (II) in an electronic device, and the provision of certain compounds of the formula (I) or (II).
    Type: Application
    Filed: March 15, 2012
    Publication date: January 30, 2014
    Applicant: Merck Patent GmbH Patents & Scientific Information
    Inventors: Teresa Mujica-Fernaud, Christof Pflumm, Irina Martynova
  • Publication number: 20140018543
    Abstract: Provided are a white-emitting monomolecular compound using excited-state intramolecular proton transfer (ESIPT) characteristics, and an organic electroluminescence device and a laser device comprising same. The white-emitting monomolecular compound according to the present invention is prepared by covalently bonding at least two types of molecules which produce different colors and have excited-state intramolecular proton transfer (ESIPT) characteristics. The white-emitting monomolecular compound according to the present invention achieves white luminescence irrespective of the concentration thereof and of the state of the materials thereof, and therefore can be used in a variety of fields including an organic electroluminescence device and a laser device.
    Type: Application
    Filed: September 12, 2013
    Publication date: January 16, 2014
    Applicants: SNU R&DB Foundation, Dongwoo Fine-Chem Co., Ltd.
    Inventors: Soo Young Park, Sang Hyuk Park, Ji Eon Kwon
  • Publication number: 20130320262
    Abstract: The present invention relates to a compound of a formula (I), (II) or (III), to the use of this compound in an electronic device, and to an electronic device comprising one or more compounds of the formula (I), (II) or (III). The invention furthermore relates to a process for the preparation of a compound of the formula (I), (II) or (III) and to a formulation comprising one or more compounds of the formula (I), (II) or (III).
    Type: Application
    Filed: January 18, 2012
    Publication date: December 5, 2013
    Applicant: MERCK PATENT GMBH
    Inventors: Irina Martynova, Amir Hossain Parham, Christof Pflumm
  • Patent number: 8598148
    Abstract: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: December 3, 2013
    Assignee: President and Fellows of Harvard College
    Inventors: Andrew G. Myers, Mark G. Charest, Christian D. Lerner, Jason D. Brubaker, Dionicio R. Siegel
  • Publication number: 20130309196
    Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: March 14, 2013
    Publication date: November 21, 2013
    Inventors: John O. Link, Jeromy J. Cottell, Teresa Alejandra Trejo Martin
  • Patent number: 8580833
    Abstract: The present invention provides imidazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use the such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: November 12, 2013
    Assignee: TransTech Pharma, Inc.
    Inventors: David Jones, Raju Bore Gowda, Rongyuan Xie
  • Publication number: 20130274256
    Abstract: Certain multi-cyclic compounds and compositions thereof are useful for reducing or inhibiting the growth of bacterial biofilms and for controlling bacterial biofilm infections. Such compounds and compositions are also useful in methods for reducing or inhibiting the growth of biofilms and for controlling bacterial biofilm infections involving biofilms.
    Type: Application
    Filed: October 11, 2012
    Publication date: October 17, 2013
    Applicant: SEQUOIA SCIENCES, INC.
    Inventor: Sequoia Sciences, Inc.
  • Patent number: 8541625
    Abstract: Cyclic alkynes (e.g., cyclooctynes such as dibenzocyclooctynes) can be photochemically generated from cyclopropenones as disclosed herein. The cyclic alkynes can be reacted (e.g., in situ) with materials having alkyne-reactive groups (e.g., azide groups in a “click” reaction). In preferred embodiments, the generation and reaction of the cyclic alkyne can proceed in the absence of a catalyst (e.g., Cu(I)). These reactions can be useful, for example, for the selective labeling of living cells that are metabolically modified with azido-containing surface monosaccharides, or for light-directed surface patterning.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: September 24, 2013
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Vladimir V. Popik, Andrei A. Poloukhtine, Geert-Jan Boons, Margaretha Wolfert
  • Publication number: 20130190508
    Abstract: Novel N-heterocyclic carbene ligand precursors, N-heterocyclic carbene ligands and N-heterocyclic metal-carbene complexes are provided. Metal-carbene complexes comprising N-heterocyclic carbene ligands can be chiral, which are useful for catalyzing enantioselective synthesis. Methods for the preparation of the N-heterocyclic carbene ligands and N-heterocyclic metal-carbene complexes are given.
    Type: Application
    Filed: March 8, 2013
    Publication date: July 25, 2013
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventor: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
  • Publication number: 20130177632
    Abstract: The present invention provides therapeutically effective 2,4,5-trisubstituted imidazole compounds, methods of preparing the same, and compositions comprising the compounds alone or in combination with other agents. The present invention further provides for the use of the compounds as anti-microbial agents. The anti-microbial properties of the compounds include anti-bacterial and/or anti-fungal activity.
    Type: Application
    Filed: February 27, 2013
    Publication date: July 11, 2013
    Inventors: Raed H. Al-Qawasmeh, Aiping H. Young, Mario Huesca, Yoon S. Lee
  • Publication number: 20130177530
    Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: March 1, 2013
    Publication date: July 11, 2013
    Applicant: Gilead Sciences, Inc.
    Inventor: Gilead Sciences, Inc.
  • Publication number: 20130164803
    Abstract: Cyclic alkynes (e.g., cyclooctynes such as dibenzocyclooctynes) can be photochemically generated from cyclopropenones as disclosed herein. The cyclic alkynes can be reacted (e.g., in situ) with materials having alkyne-reactive groups (e.g., azide groups in a “click” reaction). In preferred embodiments, the generation and reaction of the cyclic alkyne can proceed in the absence of a catalyst (e.g., Cu(I)). These reactions can be useful, for example, for the selective labeling of living cells that are metabolically modified with azido-containing surface monosaccharides, or for light-directed surface patterning.
    Type: Application
    Filed: August 6, 2012
    Publication date: June 27, 2013
    Applicant: University of George Research Foundation, Inc.
    Inventors: VLADIMIR V. POPIK, Andrei A. Poloukhtine, Geert-Jan Boons, Margaretha Wolfert
  • Patent number: 8471037
    Abstract: The present invention relates to imidazole derivatives having vinyl group represented by general formula (I) which possess electron transporting character, have a high glass transition temperature (Tg), and high decomposition temperature (Td): wherein all symbols are defined as recited in the specification. The present invention also relates to a use of the imidazole derivatives having vinyl group as a guest emitter or electron transporter in luminescent elements.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: June 25, 2013
    Assignee: Industrial Technology Research Institute
    Inventors: Chien-Hong Cheng, He-Pei Hsu, Ho-Hsiu Chou, Yu-Han Chen, Yi-Hsiang Chen
  • Publication number: 20130156732
    Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: November 16, 2012
    Publication date: June 20, 2013
    Applicant: Gilead Sciences, Inc.
    Inventor: Gilead Sciences, Inc.
  • Patent number: 8450497
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein R0, R1, R2, R3, R4 and a are defined herein.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: May 28, 2013
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Mark J. Macielag, Mingde Xia, Xiaoqing Xu
  • Publication number: 20130102775
    Abstract: The present invention is a photochromic material formed of a biimidazole compound represented by general formula (1-1): (where, R4 and R5 respectively and independently represent a halogen atom or alkyl group, R1 to R3 and R6 to R8 respectively and independently represent a hydrogen atom, halogen atom, alkyl group, fluoroalkyl group, hydroxyl group, alkoxyl group, amino group, alkylamino group, carbonyl group, alkylcarbonyl group, nitro group, cyano group or aryl group, Ar1 to Ar4 respectively and independently represent a substituted or unsubstituted aryl group, R4 may form a condensed, substituted or unsubstituted aryl ring with R3, and R5 may form a condensed, substituted or unsubstituted aryl ring with R6).
    Type: Application
    Filed: July 8, 2011
    Publication date: April 25, 2013
    Applicant: MITSUBISHI GAS CHEMICAL COMPANY, INC.
    Inventors: Takeru Horino, Atsuhiro Tokita, Toyoji Oshima
  • Publication number: 20130092922
    Abstract: The present invention relates to an electronic device comprising anode, cathode and at least one organic layer which comprises a compound of the formula (I) to (IV). The invention furthermore encompasses the use of compounds of the formula (I) to (IV) in an electronic device and to a compound of the formula (Ic) to (IVc).
    Type: Application
    Filed: May 30, 2011
    Publication date: April 18, 2013
    Applicant: Merck Patent GmbH
    Inventors: Philipp Stoessel, Arne Buesing, Dominik Joosten
  • Publication number: 20130065842
    Abstract: Heterocyclic compounds, and pharmaceutical compositions thereof, are disclosed as ROR?t modulators that have a formula represented by the following: and wherein n1, n2, R1, R2, R3, and R4 are as described herein. These compounds may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.
    Type: Application
    Filed: March 11, 2011
    Publication date: March 14, 2013
    Inventors: Dan Littman, Jun R. Huh, Wenwei Huang, Ruili Huang
  • Patent number: 8389558
    Abstract: The present invention is directed to pharmaceutical compositions comprising bendamustine and one or more amphiphilic anionic compounds and self assembled aggregates, which aggregates exhibit enhanced stability in aqueous solutions, including plasma, are disclosed. The unexpectedly enhanced stability afforded by such aggregates permits patients to be treated with bendamustine in lower and/or with less frequent dosages or to improve its therapeutic effect while using the same as presently used treatment protocol.
    Type: Grant
    Filed: July 19, 2010
    Date of Patent: March 5, 2013
    Assignee: Supratek Pharma Inc.
    Inventors: Valery Alakhov, Grzegroz Pietrzynski, Patel Kishore, Thomasz Popek
  • Patent number: 8383663
    Abstract: The present invention is directed to pharmaceutical compositions including: (a) bendamustine, (b) a first charged cyclopolysaccharide, and (c) a stabilizing agent which is a second charged cyclopolysaccharide having a charge opposite to that of the first charged cyclopolysaccharide. The composition provides unexpectedly desirable stability in reactive environments such as plasma, coupled with unexpectedly desirable anticancer activity. The compositions are suitable for injection or infusion into patients in need for treatment with bendamustine.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: February 26, 2013
    Assignee: Supratek Pharma Inc.
    Inventors: Valery Alakhov, Grzegorz Pietrzynski, Patel Kishore, Thomasz Popek
  • Publication number: 20130041153
    Abstract: The present invention relates to imidazole derivatives having vinyl group represented by general formula (I) which possess electron transporting character, have a high glass transition temperature (Tg), and high decomposition temperature (Td): wherein all symbols are defined as recited in the specification. The present invention also relates to a use of the imidazole derivatives having vinyl group as a guest emitter or electron transporter in luminescent elements.
    Type: Application
    Filed: February 3, 2012
    Publication date: February 14, 2013
    Inventors: Chien-Hong CHENG, He-Pei Hsu, Ho-Hsiu Chou, Yu-Han Chen, Yi-Hsiang Chen
  • Patent number: 8372527
    Abstract: A material for an organic electroluminescence device including at least one of compounds shown by the following formula (Ia), (Ib), (IIa), (IIb), (III), (IVa) or (IVb):
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: February 12, 2013
    Assignee: Idemitsu Kosan Co., Ltd.
    Inventors: Hironobu Morishita, Yuichiro Kawamura
  • Patent number: 8368062
    Abstract: The present invention provides a nitrogen-containing heterocyclic derivative and an organic electronic device using the same. The nitrogen-containing heterocyclic derivative that is represented by the following Formula 2 or includes two or more structures of the following Formula 2: The organic electronic device according to the present invention has excellent properties in terms of efficiency, driving voltage, and a life span.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: February 5, 2013
    Assignee: LG Chem, Ltd.
    Inventors: Dong-Hoon Lee, Tae-Yoon Park, Jae-Soon Bae, Hyun Nam, Jun-Gi Jang, Sung-Kil Hong
  • Patent number: 8329140
    Abstract: A method and system for storing and evolving hydrogen (H2) employ chemical compounds that can be hydrogenated to store hydrogen and dehydrogenated to evolve hydrogen. A catalyst lowers the energy required for storing and evolving hydrogen. The method and system can provide hydrogen for devices that consume hydrogen as fuel.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: December 11, 2012
    Assignee: Los Alamos National Security, LLC
    Inventors: David L. Thorn, William Tumas, P. Jeffrey Hay, Daniel E. Schwarz, Thomas M. Cameron
  • Publication number: 20120295318
    Abstract: Cyclic alkynes (e.g., cyclooctynes such as dibenzocyclooctynes) can be photochemically generated from cyclopropenones as disclosed herein. The cyclic alkynes can be reacted (e.g., in situ) with materials having alkyne-reactive groups (e.g., azide groups in a “click” reaction). In preferred embodiments, the generation and reaction of the cyclic alkyne can proceed in the absence of a catalyst (e.g., Cu(I)). These reactions can be useful, for example, for the selective labeling of living cells that are metabolically modified with azido-containing surface monosaccharides, or for light-directed surface patterning.
    Type: Application
    Filed: August 6, 2012
    Publication date: November 22, 2012
    Applicant: University of George Research Foundation, Inc.
    Inventors: VLADIMIR V. POPIK, Andrei A. Poloukhtine, Geert-Jan Boons, Margaretha Wolfert
  • Patent number: 8299269
    Abstract: Nor-seco-type cucurbit[n]uril compounds and methylene bridged glycoluril oligomers are produced by reacting glycoluril and formaldehyde in strong organic or mineral acid at a temperature adequate to condense the reactants. These compounds are characterized by lacking —CH2— groups rendering their internal cavities more open and, for example, more responsive to guest compounds.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: October 30, 2012
    Assignee: University of Maryland
    Inventors: Lyle David Isaacs, Wei-Hao Huang
  • Publication number: 20120241681
    Abstract: The present invention relates to compounds of formula a process for their production and their use in electronic devices, especially electroluminescent devices. When used as host material for phosphorescent emitters in electroluminescent devices, the compounds of formula I may provide improved efficiency, stability, manufacturability, or spectral characteristics of electroluminescent devices.
    Type: Application
    Filed: March 20, 2012
    Publication date: September 27, 2012
    Applicant: BASF SE
    Inventors: Thomas Schaefer, Teresa Marina Figueira Duarte, Christian Schildknecht, Nicolle Langer, Ute Heinemeyer, Heinz Wolleb, Soichi Watanabe, Christian Lennartz, Gerhard Wagenblast, Annemarie Wolleb, Kristina Bardon, FLavio Luiz Benedito
  • Patent number: RE44338
    Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: July 2, 2013
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang, Virginia M. Y. Lee, John Q. Trojanowski, Daniel M. Skovronsky
  • Patent number: RE44354
    Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form-amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: July 9, 2013
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang, Virginia M. Y. Lee, John Q. Trojanowski, Daniel M. Skovronsky